Biogen Diranersen: First Tau Drug That Works, Phase 3 Risk

Biogen (BIIB) closed July 24 at $202.19, giving the company a $29.6 billion market cap. That price bakes in a declining multiple sclerosis franchise, modest Leqembi collaboration revenue, and now a Phase 2 tau-targeting drug that just produced the first randomized evidence in history that reducing tau can slow cognitive decline in Alzheimer’s disease. The question is whether that evidence is strong enough to survive Phase 3, where Alzheimer’s drugs go to die at a 99% failure rate.

The CELIA Data: Compelling, Confusing, and Missed Primary

On July 14, 2026, Biogen presented detailed Phase 2 CELIA data at AAIC 2026 in London. The trial enrolled 416 participants with early Alzheimer’s disease (mild cognitive impairment or mild dementia) across three dose arms: 60 mg every 24 weeks, 115 mg every 24 weeks, and 115 mg every 12 weeks, all administered intrathecally via lumbar puncture. The primary endpoint was dose response on CDR-SB (Clinical Dementia Rating Sum of Boxes) at Week 76.

CELIA missed its primary endpoint. Higher doses did not produce greater clinical benefit. In fact, the lowest dose worked best.

That is the headline risk. Here is the detail that makes this worth analyzing.

The 60 mg dose (n=60), administered just twice a year, showed the largest response at 18 months compared to placebo (n=115): 26% slowing on CDR-SB (0.54 points), 42% on ADAS-Cog13, 50% on MMSE, 30% on modified iADRS, and 23% on ADCOMS. The majority of these endpoint differences achieved nominal statistical significance. The two higher doses showed smaller effects: 14% and 9% slowing on CDR-SB respectively.

On the biomarker side, diranersen produced 50 to 65% reductions in CSF total tau across all doses, with reductions maintained throughout the dosing period. In the tau PET substudy (n=131), decreases from baseline were seen across all evaluated brain regions for all doses. This is the first tau-directed therapy to demonstrate reductions in both CSF tau and brain tau pathology measured by PET in a Phase 2 study.

The biomarker data and cognitive data diverged by dose. Higher doses produced greater tau reduction but less clinical benefit. Biogen said it is analyzing why the biomarker and clinical effects diverged. That divergence is the single biggest reason to be cautious here.

Why Tau Matters and Why Every Previous Attempt Failed

Tau tangles track more closely with neurodegeneration and cognitive decline than amyloid plaques, which accumulate before symptoms. That makes tau arguably a more direct target. But every previous tau-targeting antibody has failed.

Semorinemab failed the Phase 2 TAURIEL trial in early AD (457 subjects), showing no difference in cognitive decline versus placebo. Gosuranemab failed the Phase 2 TANGO trial in early AD (654 subjects), with no effect on tau accumulation by PET and accelerated cognitive decline observed. Tilavonemab failed in progressive supranuclear palsy (378 subjects). Zagotenemab failed. J&J’s posdinemab flopped in Phase 2. UCB’s anti-tau antibody also failed.

All of these were monoclonal antibodies targeting extracellular tau. Diranersen is fundamentally different. It is an antisense oligonucleotide (ASO) that targets MAPT mRNA to reduce tau production at its source, addressing both intracellular and extracellular tau. The CELIA data suggest that reducing total tau production, rather than mopping up extracellular tau with antibodies, may be the more effective strategy. This is a genuine mechanistic insight, not a marginal improvement.

Ionis (IONS) discovered diranersen and licensed it to Biogen in December 2019. Ionis receives royalties and milestones. The drug fits Ionis’s neurology franchise alongside Spinraza (spinal muscular atrophy), Wainua (ATTR polyneuropathy), and Qalsody (ALS). Ionis closed at $56.55 on July 24.

Competitive Picture: Complementary, Not Competitive

Diranersen does not compete with Leqembi (lecanemab) or Kisunla (donanemab). Those are anti-amyloid therapies. Diranersen targets a different pathology. CELIA enrolled patients naive to anti-amyloid therapy, meaning the tau signal was independent.

This matters commercially. If diranersen reaches market, it could be used alongside anti-amyloid therapies rather than instead of them. Eisai forecasts Leqembi to reach approximately $900 million in 2026 sales, with Q1 2026 global sales of $168 million, up 74% year over year. Biogen records collaboration revenue from its Eisai partnership. A tau drug would be Biogen’s own product, with full economics.

The competitive comp here is not another tau drug, because there are no approved tau drugs. The comp is Biogen itself. At $29.6 billion market cap, Biogen is trading at roughly 3x its 2025 revenue of $9.89 billion. That is a declining MS franchise (40% of revenue) plus a growing but still sub-billion-dollar rare disease and Alzheimer’s portfolio. The market is not pricing in diranersen at all. If Phase 3 succeeds, Biogen gets a second Alzheimer’s drug with a novel mechanism, an entirely new therapy class, and a dosing schedule of twice a year that is more convenient than monthly IV anti-amyloid infusions.

Compare that to Eli Lilly (LLY), which trades at a premium partly because of Kisunla’s approval and donanemab’s potential. Lilly’s Alzheimer’s franchise is real and generating revenue. Biogen’s tau program is still Phase 2. The gap between BIIB at $29.6B and LLY at its $700B+ market cap reflects the difference between an approved amyloid drug with growing sales and an unapproved tau drug with a missed primary endpoint.

The Risk: Phase 3 Alzheimer’s Is a Graveyard

Here is the specific risk. CELIA missed its primary endpoint. The cognitive benefit was largest at the 60 mg dose (26% CDR-SB slowing), which is counterintuitive and unexplained. Nominal statistical significance on secondary endpoints is not the same as a primary endpoint win. Phase 3 Alzheimer’s trials have failed at a 99% rate historically. The phase 3 design will need to explain the dose-response inversion and prove the 60 mg effect replicates in a larger trial.

The patient population is also a question. CELIA enrolled patients naive to anti-amyloid therapy. In the real world, many early AD patients are now on Leqembi or Kisunla. Phase 3 will need to address whether diranersen works in patients already receiving anti-amyloid treatment, or whether it is only for the anti-amyloid-naive population.

There is also a safety consideration. The incidence of serious adverse events was higher at the highest dose studied. While the overall safety profile was described as generally well tolerated and over 90% of completers elected to continue into the extension study, intrathecal administration is an invasive delivery route. Twice-yearly lumbar punctures are not trivial. For a chronic neurodegenerative disease, patient acceptance of repeated spinal injections over years is an open question.

The next catalyst is Phase 3 trial design and initiation. Biogen said it plans to advance to registrational development but has not disclosed a timeline. The FDA granted Fast Track designation, which could enable rolling submission and Priority Review if Phase 3 succeeds.

Valuation: What Is a Phase 2 Tau Drug Worth?

Biogen at $202 trades below the analyst consensus price target of $220.57 (32 analysts, range $157 to $300). Guggenheim maintains a Buy with a $280 target. BofA Securities holds Neutral at $215. The stock has moved from approximately $177 in early January 2026 to $202 in late July, a 14% gain that likely reflects Leqembi momentum and the CELIA data presentation at AAIC.

The diranersen option value is not in the stock. If Phase 3 succeeds and diranersen reaches market, Biogen gains a first-in-class tau therapy for a disease affecting 55 million people worldwide. Peak sales estimates for a disease-modifying Alzheimer’s drug range from $2 billion to $5 billion annually, depending on pricing and penetration. At a conservative 4x peak sales multiple, a successful diranersen could add $8 to $20 billion in enterprise value, or $54 to $135 per share.

But Phase 3 is years away from a readout. Biogen has not even started the trial. The probability of success for a Phase 2 Alzheimer’s drug advancing to approval is estimated at 10 to 20% based on historical data. Discounting a $10 billion NPV at 10% over 5 years with a 15% success probability gives an option value of approximately $7.5 billion, or roughly $51 per share.

My take: Biogen at $202 is fairly valued on its existing franchise. The diranersen option is free upside. The CELIA data are the most compelling tau signal in Alzheimer’s history, but the missed primary endpoint and the dose-response inversion mean Phase 3 is a genuine coin flip, not a slam dunk. I would not buy Biogen solely for diranersen, but at current prices, the tau pipeline is a call option that costs nothing. For investors already holding BIIB for Leqembi and the rare disease portfolio, the CELIA data are a reason to hold, not a reason to add aggressively.

The worst-case scenario: Phase 3 fails like every other tau attempt, and Biogen is back to being a declining MS company with a Leqembi partnership. At $202, that downside is already the base case. The market has not priced in the tau upside.

For context on the broader Alzheimer’s pipeline and how biotech catalysts drive stock moves, see our Biogen Leqembi subcutaneous FDA approval coverage and our guide to PDUFA dates. For the clinical trial mechanics behind these data, our guide to reading clinical trial press releases breaks down what endpoints actually mean.

The CELIA data are real. The tau reduction is real. The cognitive signal at 60 mg is real. But until Biogen explains why the lowest dose worked best and proves it in Phase 3, this is a story about potential, not proof. The full trial details are registered on ClinicalTrials.gov (NCT05399888).